Scientific rationale for extrapolation of biosimilar data across cancer indications: case study of CT-P10.

about

Looking to the future and learning lessons from the recent past: changing stakeholder perceptions of biosimilars in cancer.

P2860

Q38686396-EC090165-47DD-49FF-A1C2-6DE113A82D4C

P2860

Scientific rationale for extrapolation of biosimilar data across cancer indications: case study of CT-P10.

Item

http://www.wikidata.org/entity/Q36366077

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Scientific rationale for extra ...... cations: case study of CT-P10.

@ast

Scientific rationale for extra ...... cations: case study of CT-P10.

@en

type

Item

label

Scientific rationale for extra ...... cations: case study of CT-P10.

@ast

Scientific rationale for extra ...... cations: case study of CT-P10.

@en

prefLabel

Scientific rationale for extra ...... cations: case study of CT-P10.

@ast

Scientific rationale for extra ...... cations: case study of CT-P10.

@en

P1476

Scientific rationale for extra ...... cations: case study of CT-P10.

@en

P2093

Bertrand Coiffier

http://www.w3.org/2001/XMLSchema#string

Hyuk-Chan Kwon

http://www.w3.org/2001/XMLSchema#string

Michinori Ogura

http://www.w3.org/2001/XMLSchema#string

Sang Wook Yoon

http://www.w3.org/2001/XMLSchema#string

P2860

B cells in rheumatoid arthritis: from pathogenic players to disease biomarkers.

A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis

FCGR3A 158V/F polymorphism and response to frontline R-CHOP therapy in diffuse large B-cell lymphoma.

Pathogenesis of human B cell lymphomas.

B lymphocytes: how they develop and function.

From the bench to the bedside: ways to improve rituximab efficacy.

The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy

Impaired early B cell tolerance in patients with rheumatoid arthritis.

Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions.

Evolution of anti-CD20 monoclonal antibody therapeutics in oncology.

P304

45-53

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON-2017-0156

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

15s

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28482699

http://www.w3.org/2001/XMLSchema#string

Scientific rationale for extrapolation of biosimilar data across cancer indications: case study of CT-P10.

about

P2860

P2860

Scientific rationale for extrapolation of biosimilar data across cancer indications: case study of CT-P10.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698